Clinical trials: Lymphoma, Hodgkins
Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell…
- Conditions
- Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma
- Trial name
- NCT05890352
- Testing
- Biospecimen Collection, Computed Tomography, Lenalidomide
- Where
- 104 sites in United States
- Volunteers
- 227 people
- Sponsor
- SWOG Cancer Research Network
Non-Hodgkin's Lymphoma
A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
This open-label, multicenter, Phase 1/1b study will evaluate the safety, tolerability, and pharmacokinetics of increasing doses of DCDS0780A in participants with relapsed or refractory B-cell non-Hodgkin's lymphoma.
- Trial name
- NCT02453087
- Testing
- DCDS0780A, Rituximab, Obinutuzumab
- Where
- 7 sites in United States
- Volunteers
- 66 people
- Sponsor
- Hoffmann-La Roche
Non-hodgkin Lymphoma
Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma
The primary objective of this study is to determine the safety and tolerability of GS-0189 (formerly FSI-189) as monotherapy and in combination with rituximab in participants with relapsed/refractory (R/R) non-Hodgkin lymphoma…
- Trial name
- NCT04502706
- Testing
- GS-0189, Rituximab
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Gilead Sciences
Lymphoma, Non-Hodgkin, Neoplasms
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas
Study CC-90010-ST-001 is an open-label, Phase 1a, dose escalation and expansion, First-in-human (FIH) clinical study of CC-90010 in subjects with advanced or unresectable solid tumors and relapsed and/or refractory advanced…
- Trial name
- NCT03220347
- Testing
- CC-90010
- Where
- 11 sites in France, Italy and 2 more
- Volunteers
- 139 people
- Sponsor
- Celgene
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase I/II trial to study the effectiveness of combining radiolabeled monoclonal antibody therapy and rituximab with and without filgrastim and interleukin-11 in treating patients who have relapsed or refractory non-Hodgkin's…
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
- Trial name
- NCT00012298
- Testing
- rituximab, yttrium Y 90 ibritumomab tiuxetan, indium In 111 ibritumomab tiuxetan
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- National Cancer Institute (NCI)
Non-Hodgkins Lymphoma, Multiple Myeloma
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
This study is evaluating the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy acalabrutinib and ACP 319 in B-cell malignancies.
- Conditions
- Non-Hodgkins Lymphoma, Multiple Myeloma, B-All
- Trial name
- NCT02328014
- Testing
- Acalabrutinib, ACP-319
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Acerta Pharma BV
Lymphoma
G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients
Primary Objectives: 1. To determine the efficacy of in vivo purging achieved by rituximab in the two groups. 2. To determine the number of apheresis procedures, total stem cell yield/kg patient body weight and the toxicity…
- Trial name
- NCT00499343
- Testing
- Etoposide, G-CSF, GM-CSF
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma
Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine
Patients with certain types of cancer require treatment with very high doses of chemotherapy. A side effect of high chemotherapy doses is damage to the bone marrow where our blood and immune system cells are produced.
- Trial name
- NCT01022021
- Testing
- Rituximab, Bendamustine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Kansas Medical Center
Non Hodgkin Lymphoma
A Study to Evaluate the Safety and Clinical Efficacy of STR-P004
This study is a single-arm, single-center, open-label, multiple-dose, dose-escalation early clinical study aimed at evaluating the safety, tolerability, and pharmacokinetic profile of STR-P004 in subjects with relapsed/refractory…
- Trial name
- NCT07003178
- Testing
- STR-P004
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Starna Therapeutics
Non-Hodgkin's Lymphoma (NHL)
Zevalin Post-marketing Surveillance for Adequateness of Image Interpretation Criteria in Japan
This study is a regulatory post-marketing surveillance of Zevalin (ibritumomab tiuxetan) in Japan. In-111 Zevalin is, at first, injected to patient for gamma scan imaging to assess biodistribution of the Zevalin.
- Trial name
- ZEVALIN-SDUI (NCT01479387)
- Testing
- [111]In-ibritumomab tiuxetan (Zevalin, BAY86-5128)
- Where
- Japan
- Volunteers
- 72 people
- Sponsor
- Bayer
Leukemia, Non-Hodgkins Lymphoma
Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders
Background: Allogeneic stem cell transplantation (SCT) has been used to treat many kinds of cancer or pre-cancerous conditions that develop in blood or immune system cells.
- Conditions
- Leukemia, Non-Hodgkins Lymphoma, Hodgkins Lymphoma, MDS
- Trial name
- NCT00973804
- Testing
- EPOCH-F/R, FLAG, Transplant Preparative Regimen (Flu/Cy/Mes)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
RATIONALE: Monoclonal antibodies, such as ofatumumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT01190449
- Testing
- ofatumumab
- Where
- 48 sites in United States
- Volunteers
- 51 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-Hodgkin's Lymphoma
Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma
The purpose of this study is to test the safety of rhIL-18 combined with ofatumumab to see what effects (good and bad) it has on subjects and their non-Hodgkin's lymphoma.
- Trial name
- NCT01768338
- Testing
- Ofatumumab combined with SB-485232
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Michael John Robertson
Lymphoma, Non-Hodgkin
Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
The purpose of this study is to assess whether copanlisib in combination with standard immunochemotherapy (rituximab in combination with bendamustine [R-B] and rituximab in combination with a 4 drug combination of…
- Trial name
- CHRONOS-4 (NCT02626455)
- Testing
- Copanlisib (BAY80-6946), Rituximab, Cyclophosphamide
- Where
- 201 sites in United States, Australia and 33 more
- Volunteers
- 551 people
- Sponsor
- Bayer
Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma
A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies
A study of CTA30X cell injection in the treatment of relapsed or refractory CD19-positive B-line hematological malignancies
- Trial name
- NCT04689204
- Testing
- CTA30X
- Where
- China
- Volunteers
- 3 people
- Sponsor
- He Huang
Lymphoma
Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma
RATIONALE: Diagnostic procedures, such as positron emission tomography (PET) using fludeoxyglucose F 18, may help in learning how well chemotherapy works to kill cancer cells and allow doctors to plan better treatment.
- Trial name
- NCT00110006
- Testing
- rituximab, cyclophosphamide, doxorubicin hydrochloride
- Sponsor
- Case Comprehensive Cancer Center
B-Cell Non-Hodgkin Lymphoma, Multiple Myeloma
Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
This clinical trial compares the effectiveness of geriatric assessment (GA) guided interventions to accelerate functional recovery after chimeric antigen receptor T-cell (CAR-T) therapy compared to standard of care (SOC) in…
- Trial name
- NCT06052826
- Testing
- Best Practice, Cognitive Intervention, Comprehensive Geriatric Assessment
- Where
- 4 sites in United States
- Volunteers
- 164 people
- Sponsor
- City of Hope Medical Center
Lymphoma
Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them.
- Trial name
- NCT00278421
- Testing
- rituximab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 78 sites in Germany, Israel and 1 more
- Volunteers
- 592 people
- Sponsor
- German High-Grade Non-Hodgkin's Lymphoma Study Group
Lymphoma
Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma
This research study is assessing the feasibility of reduced intensity allogeneic hematopoietic stem cell transplantation (HSCT) as a possible treatment for relapsed / refractory non-Hodgkin lymphoma involving the central nervous…
- Trial name
- NCT02724904
- Testing
- Allogeneic stem cell transplantation, Fludarabine, Thiotepa
- Where
- 2 sites in United States
- Sponsor
- Massachusetts General Hospital
Cancer
Study of Information Received About Fertility and Infertility in Patients Who Have Finished Treatment for Cancer
RATIONALE: Learning about the amount of information on fertility and infertility by patients before they received treatment for cancer in a comprehensive cancer center may help doctors plan the best treatment.
- Trial name
- NCT01295463
- Testing
- questionnaire administration, study of socioeconomic and demographic variables, assessment of therapy complications
- Where
- Spain
- Volunteers
- 96 people
- Sponsor
- Institut Català d'Oncologia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.